Seres Therapeutics Inc (NAS:MCRB)
$ 0.915 0.038 (4.33%) Market Cap: 156.22 Mil Enterprise Value: 176.53 Mil PE Ratio: 0 PB Ratio: 6.54 GF Score: 47/100

Seres Therapeutics Inc To Discuss 109 ECOSPOR IV Study Results Call Transcript

Jun 07, 2022 / 12:30PM GMT
Release Date Price: $4.16 (+28.79%)
Operator

Good day, and thank you for standing by. Welcome to the SER-109 ECOSPOR IV Study Results Conference Call.

(Operator Instructions)

Please be advised today's conference may be recorded.

(Operator Instructions).

I'd now like to hand the conference over to Dr. Carlo Tanzi of Investor Relations. Please go ahead.

Carlo Tanzi
Seres Therapeutics, Inc. - IR Officer

Thank you, and good morning. A press release and accompanying slide presentation highlighting the positive SER-109 and ECOSPOR IV study results became available earlier this morning and can be found on the Investors & Media section of the company's website.

I'd like to remind you that we'll be making forward-looking statements relating to the timing of completion of the BLA filing, potential approval and commercial launch of SER-109, the marketing commercial opportunity for SER-109 and the potential for SER-109 to transform the treatment of CDI. Actual results may differ materially.

Additionally, these statements are subject to certain risks and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot